Managing Advanced Urothelial Carcinoma in an Older Patient With Comorbidities: A Clinical Discussion

This segment presents an 84-year-old patient with metastatic urothelial (bladder) cancer, multiple comorbidities, and limited functional status who has completed carboplatin plus gemcitabine with stable disease but notable treatment-related cytopenias. The discussion centers on how to balance disease control, toxicity, and the patient’s clearly stated goals: maintaining independence, avoiding further chemotherapy side effects, and minimizing hospitalization risk.

The speakers explore the role of maintenance immune checkpoint blockade in this context, emphasizing its distinct toxicity profile and the possibility of durable benefit, while acknowledging that immunotherapy is not risk-free. They explain why “watch and wait” can be particularly risky in frail patients with borderline performance status, where rapid progression may eliminate opportunities for further treatment. The segment also highlights how real-world data support the use of immunotherapy in patients who would have been excluded from many trials, and how biomarker testing and careful shared decision-making shape individualized care.